VANCOUVER, British Columbia, May 03, 2017 (GLOBE NEWSWIRE) — Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, is pleased to announce that Qu Biologics’ scientists will be presenting their research findings at several upcoming international scientific meetings. The presented data includes findings from Qu Biologics’ randomized, controlled trial in Crohn’s disease for their lead immunomodulatory product, QBECO, which targets the gastrointestinal tract, as well as preclinical data for QBKPN, which restores innate immune function in the lungs to treat lung cancer, COPD and asthma.
- Dr. Hal Gunn, Qu Biologics’ CEO, has been selected to present data from QBECO-01, Qu Biologics’ recently completed 68-patient double-blind randomized placebo-controlled trial, at Digestive Disease Week (DDW) in Chicago, on May 7th. Digestive Disease Week is the world’s foremost gastroenterology annual conference. Conference attendees can learn more about the study from Dr. Gunn at Poster SU1928.
- Dr. Mark Bazett, Preclinical Lead at Qu Biologics, will be presenting new preclinical research on SSI treatment in lung cancer at IMMUNOLOGY 2017, the world’s leading immunology meeting taking place in Washington D.C. from May 12-16, 2017. He will give a talk and poster presentation during the Novel Strategies for Cancer Vaccines Symposium on May 12th, from 2:30pm to 4:00pm.
- Dr. Shirin Kalyan, Qu Biologics’ Director of Scientific Innovation, was selected to present new findings on the mechanism of action and efficacy of SSIs for the treatment of cancer at the upcoming Summit for Cancer Immunotherapy Conference taking place in Ottawa, June 25-28. The conference is hosted by BioCanRx, a Network of Centres of Excellence focused on advancing the development of biotherapeutics that have the greatest potential to significantly improve and transform cancer treatment.
More information about the content of these presentations will be available on the Qu Biologics website post-embargo following the respective conferences.
About Qu Biologics
Qu Biologics is a Vancouver-based private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSI), a novel class of immunotherapies. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many conditions including cancer, inflammatory bowel disease, inflammatory lung disease and arthritis. SSIs are a broad platform technology being tested in multiple disease indications, including Health Canada approved clinical trials in lung cancer, Crohn’s disease and Ulcerative Colitis.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally.
Qu Biologics Inc. cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Qu Biologics’ forward-looking statements due to the risks and uncertainties inherent in Qu Biologics’ business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.
CONTACT: For more information regarding this press release,
contact: Hal Gunn, MD CEO
Qu Biologics Inc.